In the News
Alzheimer’s Research and Treatment Center
Alzheimer’s Research and Treatment Center integral in getting approval of new treatment.
On Friday, Jan. 6, 2023, Lecanemab, a treatment for mild cognitive impairment due to Alzheimer’s Disease and mild Alzheimer’s Disease, was approved for use by the Food and Drug Administration.
Alzheimer’s Research and Treatment Center integral in getting approval of new treatment.
On Friday, Jan. 6, 2023, Lecanemab, a treatment for mild cognitive impairment due to Alzheimer’s Disease and mild Alzheimer’s Disease, was approved for use by the Food and Drug Administration.
Lecanemab in Early Alzheimer’s Disease.
Dr. David Watson of ARTC is one of the primary author's of this article on Lecanemab and Alzheimer's Disease. The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal...
Positive Topline Results from the Clinical Trial of Lecanemab.
In September 2022, Eisai Co. and Biogen Inc. announced very positive topline results from the clinical trial of Lecanemab, an investigational treatment for mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s Disease. Eisai will be presenting the complete Clarity AD results at...
A Breakthrough in Alzheimer’s Disease.
Dr. Watson at ARTC is the world’s leading investigator for the Lecanemab compound. On September 27, 2022 Eisai Co.,LTD and Biogen Inc. released the following statement.
Nationally Recognized Treatment Center located in the heart of Palm Beach and Martin counties.
Wellington Location
2767 S. State Road 7, Suite 300
Wellington, FL 33414
(561) 209-2401
Stuart Location
1111 SE Indian Street, Suite 102
Stuart, FL 34997